PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #POETYK--Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults.
Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck.
Much of this was attributable to the fine performance of its growth portfolio. This lineup of medicines should continue to do well for the pharmaceutical giant.
Bristol Myers Squibb reported a first-quarter profit that beat Wall Street expectations on Thursday, helped by better-than-expected growth of blood thinner Eliquis as well as newer cancer medicines.